The Cost Barrier: Why Providers Need to Address Uceris Affordability

Prescribing Uceris (Budesonide ER) for ulcerative colitis is a sound clinical decision for many patients with active, mild to moderate disease. But even the best treatment plan fails if the patient can't afford to fill the prescription.

Brand-name Uceris carries a cash price of $1,400 to $2,330 for 30 tablets. Even with insurance, patients may face copays of $100 to $500+ depending on formulary tier placement. For patients without insurance, the cost can be prohibitive.

As prescribers, we have a direct role in helping patients access affordable treatment. This guide provides a comprehensive overview of cost-reduction strategies — from generic substitution to manufacturer programs to patient assistance — that can be implemented at the point of prescribing.

Generic Budesonide ER: The First-Line Cost Strategy

Generic Budesonide ER 9 mg extended-release tablets are FDA-approved and therapeutically equivalent to brand-name Uceris. For most patients, generic substitution should be the default approach unless there is a specific clinical reason to require the brand.

Generic Pricing

• Cash price: $150 to $630 for 30 tablets (varies significantly by pharmacy)
• With discount card (e.g., GoodRx): As low as $194 for 30 tablets
• Insurance copay: Typically preferred generic tier — $10 to $50 at most commercial plans

Clinical Considerations for Generic Substitution

The generic formulation uses the same active ingredient, strength, and extended-release mechanism. Bioequivalence has been demonstrated through FDA-required studies. In practice, most patients tolerate the switch without any change in efficacy or side effect profile.

When prescribing, consider writing "Budesonide ER 9 mg" rather than "Uceris" to allow automatic generic substitution at the pharmacy. Alternatively, ensure the prescription does not specify "DAW" (dispense as written) unless clinically warranted.

Manufacturer Savings Programs

Bausch Health / Salix Savings Card

Bausch Health (parent company of Salix Pharmaceuticals) offers a manufacturer savings card for patients with commercial insurance:

• Copay reduction: As low as $30 per fill
• Eligibility: Commercially insured patients only
• Exclusions: Not valid for patients covered by Medicare, Medicaid, Tricare, or other government-funded insurance programs
• Enrollment: Patients can enroll online through the Bausch Health website or through their prescriber's office

This is a straightforward program to implement. Consider having your office staff keep enrollment forms available or bookmark the online enrollment portal for quick patient access during visits.

When to Use the Savings Card vs. Generic

For commercially insured patients whose plans cover brand Uceris but at a high copay, the savings card may reduce costs below what the generic would cost. Run the numbers:

• If brand copay with savings card = $30 and generic copay = $40, the brand + card is actually cheaper
• If generic copay = $15 and brand copay with card = $30, generic is the better value

In practice, the generic with insurance coverage is usually the most cost-effective option, but the savings card serves as an excellent backup when patients experience generic supply issues or their plan doesn't cover the generic.

Patient Assistance Programs (PAPs)

Bausch Health Patient Assistance Program

For uninsured or underinsured patients who meet income eligibility requirements, Bausch Health offers a formal PAP:

• Benefit: Free medication for qualifying patients
• Eligibility: Uninsured or underinsured patients meeting income thresholds
• Application: Available at bauschhealthpap.com or by calling 1-855-770-0424
• Processing time: Typically 2-4 weeks from application submission

Providers play a critical role in PAP enrollment. The application requires prescriber information and often a clinical attestation. Consider designating a staff member to manage PAP applications as part of your practice workflow.

Prescription Hope

Prescription Hope is a third-party organization that facilitates access to manufacturer PAPs:

• Cost: $70/month flat fee for qualifying patients
• Process: They handle the paperwork and interface with the manufacturer on the patient's behalf
• Useful for: Patients who find the direct PAP application process challenging or who don't qualify for the manufacturer's free program

Discount Card Programs for Uninsured or High-Copay Patients

For patients paying cash or facing high copays, prescription discount cards can provide significant savings on generic Budesonide ER. Key programs to recommend:

• GoodRx: Prices as low as $194 for 30 tablets of generic Budesonide ER
• SingleCare: Competitive pricing at major chain pharmacies
• RxSaver: Compares prices across nearby pharmacies
• Optum Perks: Free discount card accepted at most pharmacies

Important note for patients: Discount cards cannot be combined with insurance. They are an alternative payment method, not a supplement. Patients should compare their insurance copay with the discount card price and use whichever is lower.

Insurance Navigation Strategies

Prior Authorization Best Practices

Most payers require prior authorization for Uceris, with common criteria including:

• Documented diagnosis of active, mild to moderate ulcerative colitis
• Trial and failure (or documented intolerance) of at least one 5-ASA agent (Mesalamine)
• Clinical documentation supporting the need for corticosteroid therapy

To expedite approvals:

• Submit PA requests with complete clinical documentation upfront — colonoscopy/sigmoidoscopy findings, failed medication trials, current symptom severity
• Use payer-specific PA forms when available (most are accessible through electronic PA platforms like CoverMyMeds or Surescripts)
• Include relevant lab work (CRP, ESR, fecal calprotectin) to support disease activity
• Document failed step therapy medications with dates, doses, and reasons for discontinuation

Appeals Process

Initial PA denials are common and should not be treated as final. The appeals process offers several opportunities:

• First-level appeal: Peer-to-peer review with the plan's medical director — often the most effective step
• Second-level appeal: Written submission with additional clinical evidence
• External review: Available in most states for final denials

Peer-to-peer reviews are particularly effective for Uceris because the clinical rationale — locally-acting corticosteroid with fewer systemic effects than Prednisone — is well-supported by evidence and resonates with reviewing physicians.

Addressing Availability Issues

Cost savings are meaningless if the patient can't find the medication. Uceris and generic Budesonide ER have experienced intermittent supply issues since 2022, with regional variability persisting into 2026.

Practical steps providers can take:

• Direct patients to Medfinder — A real-time pharmacy availability tool that shows which pharmacies currently have Budesonide ER in stock
• Recommend specialty pharmacies — Pharmacies specializing in GI medications often maintain more reliable supply
• Consider mail-order — Higher-volume operations are less affected by local supply gaps
• Build pharmacy relationships — Identify 2-3 pharmacies in your area that consistently stock Budesonide ER and direct patients there

For a deeper dive into supply issues, see our provider-focused article on Uceris shortage: what providers and prescribers need to know in 2026.

Implementing a Cost-Conscious Prescribing Workflow

To systematically address medication costs for UC patients, consider building the following steps into your practice workflow:

At the Point of Prescribing

1. Default to generic Budesonide ER — Write the generic name unless brand is clinically required
2. Verify insurance coverage — Use real-time benefit check (RTBC) tools in your EHR to see the patient's expected copay before they leave the office
3. Initiate PA proactively — Submit prior authorization at the time of prescribing, not after a pharmacy rejection
4. Discuss cost — Ask patients about their financial concerns. Many won't volunteer this information but will abandon prescriptions they can't afford.

For Uninsured Patients

1. Recommend GoodRx or SingleCare for generic Budesonide ER
2. Initiate Bausch Health PAP application
3. Consider Prescription Hope ($70/month) as an intermediate option
4. Explore state pharmaceutical assistance programs (SPAPs) if applicable

For Commercially Insured Patients with High Copays

1. Enroll in Bausch Health savings card (copay as low as $30)
2. Compare brand + savings card vs. generic pricing
3. Appeal denied PAs — especially through peer-to-peer review

For Government-Insured Patients (Medicare/Medicaid)

1. Generic Budesonide ER is typically covered at preferred tier
2. Bausch Health PAP may be available for Medicare patients in the coverage gap
3. Extra Help / Low-Income Subsidy programs can reduce Part D costs
4. State pharmaceutical assistance programs may supplement coverage

Patient Education Materials

Supplement your in-office discussion with our patient-facing resources:

• How to Save Money on Uceris: Coupons, Discounts & Patient Assistance — Comprehensive patient guide to all savings options
• How to Check If a Pharmacy Has Uceris in Stock — Step-by-step guide for patients navigating availability issues
• What Is Uceris: Uses, Dosage & What You Need to Know — General medication education for newly prescribed patients

Conclusion

Medication adherence in ulcerative colitis is directly linked to outcomes — and cost is one of the most significant barriers to adherence. By systematically incorporating generic substitution, manufacturer programs, patient assistance, and insurance navigation into your prescribing workflow, you can help ensure that patients who need Budesonide ER can actually access and afford it.

The combination of informed prescribing, proactive insurance management, and tools like Medfinder for real-time availability gives providers and patients the best chance of successful, uninterrupted treatment.

For additional provider resources on managing Uceris prescriptions, see our guide on how to help your patients find Uceris in stock.